At the beginning of COVID-19, we underlined that this pandemic was a new challenge for rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral disease on the natural history of many rheumatic diseases and, on the other hand, to define the beneficial or harmful effects of the synthetic or targeted therapies used for their treatment. In addition, we have postulated that in view of the common pathogenetic mechanisms involved, the therapeutic armamentarium currently employed in the management of viral or idiopathic systemic autoimmune rheumatic diseases could be useful to control the “cytokine storm” induced by SARS-COV-2. One year later, in the present review we have analysed the progress of the knowledge on both these aspects and updated the algorithms initially proposed for a rational use of the synthetic and targeted anti-inflammatory and immunomodulatory agents in the management of COVID-19.

Puxeddu, I., Ferro, F., Bartoloni, E., Elefante, E., Baldini, C., Scire, C., et al. (2021). COVID-19: The new challenge for rheumatologists. One year later. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39(1), 203-213.

COVID-19: The new challenge for rheumatologists. One year later

Scire C. A.;
2021

Abstract

At the beginning of COVID-19, we underlined that this pandemic was a new challenge for rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral disease on the natural history of many rheumatic diseases and, on the other hand, to define the beneficial or harmful effects of the synthetic or targeted therapies used for their treatment. In addition, we have postulated that in view of the common pathogenetic mechanisms involved, the therapeutic armamentarium currently employed in the management of viral or idiopathic systemic autoimmune rheumatic diseases could be useful to control the “cytokine storm” induced by SARS-COV-2. One year later, in the present review we have analysed the progress of the knowledge on both these aspects and updated the algorithms initially proposed for a rational use of the synthetic and targeted anti-inflammatory and immunomodulatory agents in the management of COVID-19.
Articolo in rivista - Review Essay
COVID-19; Cytokines; Pathogenesis; Rheumatic diseases; SARS-CoV-2; Synthetic; Targeted therapy;
English
203
213
11
Puxeddu, I., Ferro, F., Bartoloni, E., Elefante, E., Baldini, C., Scire, C., et al. (2021). COVID-19: The new challenge for rheumatologists. One year later. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39(1), 203-213.
Puxeddu, I; Ferro, F; Bartoloni, E; Elefante, E; Baldini, C; Scire, C; Talarico, R; Migliorini, P; Mosca, M; Bombardieri, S
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/367322
Citazioni
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 5
Social impact